Cellular Origin of Renal Cell Carcinoma — An Immunohistological Study on Monoclonal Antibodies

Fl, Gu; Sl, Cai; Bj, Cai; Cp, Wu

doi:10.1080/21681805.1991.12068889

Cited by 8 publications

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T‐16 antigen (Trop‐2, MOv‐16)

Schön

Orfanos

1995

Intl Journal of Cancer

View full text Add to dashboard Cite

The regulation of synthesis and post-translational processing of the T-16 antigen, a human cell-surface glycoprotein of 50 to 60 kDa, was investigated in normal and transformed human keratinocytes in vitro. Normal keratinocytes of interfollicular and follicular origin were compared with squamous-cell-carcinoma lines, spontaneously immortalized keratinocytes, and SV-40 transformed keratinocytes. FACS analysis and radio-immunoprecipitation showed that the synthesis and expression of T-16 was 3- to 4-fold higher in transformed keratinocytes than in their normal counterparts. In normal keratinocytes, no quantitative differences were observed among freshly prepared cells, primary cultures and sub-cultures. In SDS-PAGE, a single broad band at 50 to 60 kDa was observed in normal keratinocytes, whereas 2 bands at 42 and 45 to 55 kDa were detected after transformation. Tunicamycin treatment of living cells and glycosidase digestion of immunopurified T-16 antigen revealed this molecular heterogeneity to be due to different N-glycosylation in normal and transformed keratinocytes. In pulse-chase experiments, 2 distinct precursor proteins at 38 and 42 kDa were detected in transformed keratinocytes, whereas in normal cells the 38-kDa signal was dramatically decreased. These findings indicate that quantitative and qualitative changes of T-16 mark the transformation process of human keratinocytes, showing similar post-translational alterations in all transformed populations investigated.

show abstract

Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T‐16 antigen (Trop‐2, MOv‐16)

Schön

Orfanos

1995

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

The Heterogeneity Metabolism of Renal Cell Carcinomas

Zarisfi

Nguyen

Nedrow

et al. 2021

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

According to data from the American Cancer Society, cancer is one of the deadliest health problems globally. Annually, renal cell carcinoma (RCC) causes more than 100,000 deaths worldwide [1–4], posing an urgent need to develop effective treatments to increase patient survival outcomes. New therapies are expected to address a major factor contributing to cancer’s resistance to standard therapies: oncogenic heterogeneity. Gene expression can vary tremendously among different types of cancers, different patients of the same tumor type, and even within individual tumors; various metabolic phenotypes can emerge, making singletherapy approaches insufficient. Novel strategies targeting the diverse metabolism of cancers aim to overcome this obstacle. Though some have yielded positive results, it remains a challenge to uncover all of the distinct metabolic profiles of RCC. In the quest to overcome this obstacle, the metabolic oriented research focusing on these cancers has offered freshly new perspectives, which are expected to contribute heavily to the development of new treatments.

show abstract

The Metabolism of Renal Cell Carcinomas and Liver Cancer

Nguyen

2018

The Heterogeneity of Cancer Metabolism

View full text Add to dashboard Cite

According to data from the American Cancer Society, cancer is one of the deadliest health problems globally. Annually, renal cell carcinoma (RCC) and liver cancer cause more than 100,000 and 800,000 deaths worldwide, respectively [1–4], creating an urgent need to develop effective therapeutic treatments to increase patient survival outcomes. New therapeutic treatments are expected to address a major factor contributing to cancer’s resistance to standard therapies: oncogenic heterogeneity. Because gene expression can vary tremendously among different types of cancers, different patients of the same tumor type, and even within individual tumors, various metabolic phenotypes can emerge, making single-therapy approaches insufficient. This heterogeneity translates into changes in the landscape of metabolic enzymes and biomolecules within both the cancer cell and tumor microenvironment. Novel strategies targeting the diverse metabolism of cancers aim to overcome this obstacle, and though some have yielded positive results, it remains a challenge to uncover all of the distinct metabolic profiles of RCC and liver cancer. Nonetheless, the metabolic-oriented research focusing on these cancers has offered different, fresh new perspectives, which are expected to contribute heavily to the development of new therapeutic treatments.

show abstract

Cellular Origin of Renal Cell Carcinoma — An Immunohistological Study on Monoclonal Antibodies

Cited by 8 publications

References 5 publications

Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T‐16 antigen (Trop‐2, MOv‐16)

Transformation of human keratinocytes is characterized by quantitative and qualitative alterations of the T‐16 antigen (Trop‐2, MOv‐16)

The Heterogeneity Metabolism of Renal Cell Carcinomas

The Metabolism of Renal Cell Carcinomas and Liver Cancer

Contact Info

Product

Resources

About